Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AlloCAR-NKT
- Development stage
- Preclinical
- Lead developer
- Allogene Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
AlloCAR-NKT is an investigational allogeneic cellular therapy comprised of natural killer T cells (NKT) genetically engineered to express a chimeric antigen receptor (CAR), allowing them to target cancer cells via several mechanisms[1]. These cells can recognize and kill tumor cells through a combination of CAR recognition (of a specific tumor antigen), T-cell receptor (TCR) engagement (primarily recognizing CD1d), and natural killer receptor (NKR) activation (binding to NK ligands such as NKG2D and DNAM-1 ligands on tumor cells), enabling triple- or double-targeting of both hematologic malignancies and solid tumors. AlloCAR-NKT is designed for off-the-shelf use, generated from healthy donor hematopoietic stem cells, and may overcome antigen escape and reduce cytokine release syndrome compared to conventional CAR-T therapies[1].
- Brand names
- AlloCAR-NKT
- Other names
- AlloCAR-NKT
02
Targets
BCMA (B-cell maturation antigen)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on AlloCAR-NKT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AlloCAR-NKT.